Commonwealth of Pennsylvania Public School Empls Retrmt SYS Reduces Stock Position in Revvity, Inc. (NYSE:RVTY)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS trimmed its stake in shares of Revvity, Inc. (NYSE:RVTY) by 3.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,877 shares of the company’s stock after selling 972 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Revvity were worth $2,888,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Empowered Funds LLC purchased a new position in Revvity in the third quarter worth about $227,000. Natixis Advisors LLC increased its position in shares of Revvity by 17.9% during the 3rd quarter. Natixis Advisors LLC now owns 12,499 shares of the company’s stock valued at $1,597,000 after purchasing an additional 1,901 shares during the last quarter. Quest Partners LLC bought a new position in shares of Revvity in the 3rd quarter worth approximately $126,000. Pathstone Holdings LLC boosted its holdings in shares of Revvity by 70.0% in the third quarter. Pathstone Holdings LLC now owns 21,358 shares of the company’s stock worth $2,728,000 after buying an additional 8,791 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Revvity during the third quarter valued at approximately $393,000. Institutional investors own 86.65% of the company’s stock.

Insider Buying and Selling at Revvity

In related news, insider Tajinder S. Vohra sold 5,492 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the transaction, the insider now directly owns 19,652 shares in the company, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now directly owns 33,400 shares of the company’s stock, valued at approximately $4,232,782. The trade was a 31.23 % decrease in their position. The disclosure for this sale can be found here. 0.60% of the stock is owned by company insiders.

Revvity Stock Up 1.2 %

RVTY opened at $108.60 on Tuesday. Revvity, Inc. has a 52 week low of $97.32 and a 52 week high of $129.50. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. The firm has a 50-day simple moving average of $116.15 and a two-hundred day simple moving average of $117.48. The company has a market capitalization of $13.05 billion, a PE ratio of 49.14, a price-to-earnings-growth ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the previous year, the firm posted $1.25 earnings per share. Analysts forecast that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date is Thursday, April 17th. Revvity’s payout ratio is 12.67%.

Analysts Set New Price Targets

Several research firms have weighed in on RVTY. KeyCorp increased their price target on shares of Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Barclays lifted their price objective on Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Sanford C. Bernstein lowered shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price for the company. in a report on Friday, January 10th. Bank of America raised shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price target on the stock in a report on Friday, December 13th. Finally, Raymond James reissued an “outperform” rating and issued a $145.00 price objective (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Revvity currently has a consensus rating of “Moderate Buy” and an average target price of $136.25.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.